

GENOMIC VALLEY BIOTECH LIMITED

[CIN : L01122HR1994PLC033029]



4 KM Stone, Berrl Chhara Road, P.O. Tanda Herl, Tehsil
Bahadurgarh, District Jhajjar, HARYANA, INDIA - 124 507

genomicvalley@gmail.com

www.genomicvalley.com

+91 9811341542

Dated: 31st May, 2022

To,
BSE Limited
PhirozeJeejeebhoy Towers,
Dalal Street, Fort
Mumbai-400001
Email ID: corp.relations@bseindia.com

Ref: Genomic Valley Biotech Limited (539206/ GVBL)

Sub: Submission of Newspaper Advertisements of the Extract of Audited Financial Results approved in Board Meeting of the Company held on 28.05.2022

Dear Sir/Madam,


Pursuant to the Regulation 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the copy of Newspaper advertisements of the Extract of Audited Financial Results for the quarter and year ended 31.03.2022 approved in Board Meeting of the Company held on 28.05.2022.

Kindly take the above information into your records.

Thanking you.

Yours faithfully,

For **Genomic Valley Biotech Limited**



Hanuman Prasad
Company Secretary & Compliance Officer
M.No.: 46027

2. The Statutory Auditors have reviewed these financial results pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
 3. Segment reporting as defined in Accounting Standard-17 is not applicable as the Company is engaged in NBFC Business.
 4. Other Expenses for Quarter ended as on March 31, 2022 included donation of Rs 700 thousand.
 5. The figures for the quarter ended 31 March, 2022 are the balancing figures between figures in respect of audited year to date published figures upto March 31, 2022 and unaudited figures uploaded upto 3rd quarter ended on 31 December, 2021.
 6. The above is an extract of the detailed format of Quarterly & Twelve Months Financial Results - as per IND AS compliant filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarterly and Twelve Months Financial Results are available on Company's website at www.jtel.co.in and on the Stock Exchange website, www.mseil.in

For, **JAGAT TRADING ENTERPRISES LIMITED**
 Sd/-
(Praveen Kumar Goel)
 Chairman
 DIN No: 00021153

Place: New Delhi
 Date: 30th May, 2022

X. Net Profit/(Loss) for the period from continuing operation (VII-VIII)	5.49	4.74	21.46
XI. Net Profit/(Loss) for the period from discontinuing operation	0.00	0.00	0.00
XII. Tax expense from discontinuing operations	0	0	0
Net Profit/(Loss) for the discontinuing operations after Tax (XII-XIII)	0	0	0
Net Profit/(Loss) for the period (X+XI+XII)	5.49	4.74	21.46
Net Earnings Per Equity Share			
(a) Basic	1.75	0.16	5.55
(b) Diluted	0	0	0
Paid up equity share capital (Face Value of the Share shall be indicated)	31.43	31.43	31.43
Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	148.18	148.18	148.18

PART-II - Information for the fourth quarter ended 31/03/2022

A PARTICULARS OF SHAREHOLDING			
1. Public shareholding			
- Number of Shares	125500	125500	125500
- Percentage of Shareholding	39.93%	39.93%	39.93%
2. Promoters & Promoter group shareholding			
a) Pledged / Encumbered			
- Number of Shares	0	0	0
- Percentage of shares (as a % of the total shareholding of promoter & promoter group)	0	0	0
- Percentage of shares (as a % of the total share capital of the company)	0	0	0
b) Non-encumbered			
- Number of Shares	188750	188750	188750
- Percentage of shares (as a % of the total shareholding of promoter & promoter group)	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	60.07%	60.07%	60.07%
Particulars			
B INVESTOR COMPLAINTS			
Pending at the beginning of the quarter			
Received during the quarter			
Disposed of during the quarter			
Remaining unresolved at the end of the quarter			

GENOMIC VALLEY BIOTECH LIMITED

Regd. Off: 4 K.M. Stone, Beri Chhara Road, Village- Kherka Musalman, P.O. Tandahehi, Tehsil-Bahadurgarh, Distt-Jhajjar, Haryana-124507
 CIN: L01122HR1994PLC033029 ; Tele: +91-9811341542
 Email: genomicvalley@gmail.com; Visit: <http://www.genomicvalley.com>

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022 (Amount in ₹)

Sr. No.	Particulars	Quarter ended		Year ended		
		31-Mar-22 Audited	31-Dec-21 Un-Audited	31-Mar-21 Audited	31-Mar-22 Audited	31-Mar-21 Audited
1	Total income from operation	55,522	1,030,788	246,116	1,545,710	2,110,026
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary Item)	-2,657,363	108,497	-3,263,376	-4,208,275	-5,018,143
3	Net Profit / (Loss) for the period before tax (after Exceptional and /or Extraordinary Item)	1,534,421	108,497	-3,263,376	-16,492	-5,018,143
4	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Item)	1,457,511	108,497	-3,835,747	-93,402	-5,590,514
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	1,457,511	108,497	-3,835,747	-93,402	-5,590,514
6	Equity Share Capital (30,54,500 Equity Shares @ Rs. 10 each)	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year				-1,758,757	14,334,645
8	Earnings Per Share					
	(a) Basic	0.48	0.04	-1.26	-0.03	-1.88
	(b) Diluted	0.48	0.04	-1.26	-0.03	-1.83

Notes:

- The above extracts of Financial Results were reviewed by the Members of Audit Committee and were thereafter approved by the Board of Directors at their respective Meeting held on May 28, 2022 and concluded on May 29, 2022.
- The above is an extract of the detailed format of quarterly and yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarterly and yearly Financial Results are available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.genomicvalley.com).

For and on behalf of the Board of Genomic Valley Biotech Ltd Sd/-

Yogesh Agrawal
 (Chairman & Managing Director)
 DIN-01165288

Place: Delhi
 Dated: May 30, 2022

Add: G-74 Pushkar Enclave Paschim Vihar, New Delhi-110083

EAST BUILDTECH LIMITED

CIN: L74999DL1984PLC018610
 Regd Office: D-3/2, Okhla Industrial Area, Phase-II, New Delhi-110020, Ph. 011-47105100
 Email: secretarial@ebi.co.in Website: www.ebi.co.in

Extract of Audited Financial Results for the Quarter and Year ended 31st March, 2022 Rs. in Lacs

S. No.	Particulars	For the Quarter Ended	For the Quarter Ended	For the Year ended	For the Year ended
		31.03.2022	31.03.2021	31.03.2022	31.03.2021
		Audited	Audited	Audited	Audited
1	Total income from operations (net)	35.10	4.74	69.76	36.54
2	Profit / (Loss) before exceptional and tax	11.48	(2.88)	3.00	0.37
3	Net Profit/(Loss) for the period after tax (after exceptional items)	7.99	(3.48)	1.70	(1.23)
4	Total comprehensive income	8.02	(3.74)	1.71	(1.27)
5	Equity share capital	190.76	190.76	190.76	190.76
6	Earnings per share (EPS) (after extraordinary items) (Of Rs 10/- each) (not annualised)				
	a) Basic	0.43	(0.19)	0.09	(0.07)
	b) Diluted	0.43	(0.19)	0.09	(0.07)

Notes:

- Statement of Segment wise revenue, results and capital employed for quarter and year ended March, 2022

Rupees in Lakhs

Particulars	QUARTER ENDED	YEAR ENDED
-------------	---------------	------------

पंजाब नैशनाल बैंक

CIRCLE SASTRA CENTRE CIRCLE OFFICE, REEDGANJ, PH.NO. 05278-244377 FAX 240559 E-MAIL

POSSESSION NOTICE (for Int)

Whereas, the undersigned being the Authorized Officer of the Punjab Reconstruction of Financial Assets and Enforcement of Security Interest under Section 13(12) read with Rule 3 of the Security Interest (Enforcement) on the dates mentioned against each account calling upon the respective account holder to repay the amount, notice is hereby given to the borrower or guarantor's /mortgagor's attention is invited to provisions of sub-section 4 of Section 13 of Act read with Rule 8 of the Security Interest to deal with the properties and any dealing with the property/ies will be deemed to be null and void. The borrowers in part to deal with the properties and any dealing with the property/ies will be deemed to be null and void. The borrowers in part to deal with the properties and any dealing with the property/ies will be deemed to be null and void.

S. No. of the Branch	Name of the Account/ Borrower (Owner of the Property)	Description of the Mortgage (all the part & parcel property consist)	
1	Kadipur, Sultampur	(1) M/s Pandey Building Material (Prop. Vinod Kumar Pandey) Chanda Road, Near Indian Oil Petrol Pump Kadipur Dist: Sultampur, UP (2) Mr. Vinod Kumar Pandey S/o Shri Ram Lout Pandey (Prop. of the firm) Chanda Road, Near Indian Oil Petrol Pump, Kadipur, Dist: Sultampur, UP (3) Mr. Ram Lout Pandey (Guarantor) Since deceased now represented by his legal heirs namely:- (i) Smt. Raj Kumari, W/o of Late Ram Lout Pandey (ii) Sri Kall Prasad S/o of Late Ram Lout Pandey (iii) Sri. Pawan Kumar S/o of Late Ram Lout Pandey (iv) Smt. Rekha D/o Late Ram Lout Pandey (v) Sri Vinod Kumar S/o of Late Ram Lout Pandey (vi) Smt. Surekha D/o of Late Ram Lout Pandey (vii) Sri Arun Kumar S/o of Late Ram Lout Pandey, All (S/N. (i) to (vii) residing at Vill & PO: Palla Gulpur, Mohullah: Vivekanand Nagar, Pargana Aldemau Tehsil: Kadipur Dist: Sultampur	1) House No. 799 address sq. feet over Khata No: Land: Mohullah: Vivekanand Nagar, Pargana Aldemau Tehsil: Kadipur Dist: Sultampur, UP (2) House No. 741/1 address sq. feet over Khata No: 1559, 1561 Ka. 6, Vivekanand Nagar, Pargana Aldemau Tehsil: Kadipur, Town area Sultampur owned by S. Pandey S/o Mr. Ram K. vide Regd. Sale Deed 03/07/2004, Bounded by land, West: Cultivative land South: Cultivative land South: kachcha 8 feet 3 inch. 3) One Kta: House area Mohullah: Vivekanand Nagar, Pargana Aldemau Tehsil: Kadipur, Town area Sultampur owned by S. Pandey S/o Mr. Ram K. vide Regd. Sale Deed 03/07/2004, Bounded by West: Road Kadipur to house of Rai Narayan & Shail Kumar
2	Kadipur	(1) M/s Akib Communication House No. 970 area 121	

(after exceptional and/or extraordinary items)					
4 Net Profit for the period after tax (after exceptional and/or extraordinary items)	101.67	11.81	-127.17	-56.32	26.18
5 Total Comprehensive Income for the period (Comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax))	101.67	11.81	-127.17	-56.32	26.18
6 Paid up Equity Share Capital (Face value of Rs. 10/- each)	300.00	300.00	300.00	300.00	300.00
7 Reserve (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of Previous Year	311.53	206.66	367.66	311.53	367.66
8 Earnings Per Share (Face value of Rs. 10/- each) (Not Annualised)					
Basic:	3.39	0.39	-4.24	-1.87	0.87
Diluted:	3.39	0.39	-4.24	-1.87	0.87

Note:
a) The above audited results for the quarter and year ended 31st March, 2022 have been reviewed by the Audit committee and approved by the Board of Directors at their respective meetings held on 30th May, 2022. The Financial results for the year ended 31st March, 2022 have been audited by the statutory Auditors of the Company.
b) The above is an extract of the detailed format of Audited Financial results for the year ended and Quarter ended on March 31, 2022 filed with stock exchange under regulation 33 of the SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015. The full format of the Audited financial results and quarter ended on March 31, 2022 are available on company's website www.internationalsecuritiesltd.com and on the website of the Metropolitan Stock Exchanges.

On behalf of the Board of Directors
Rajeev Kumar Gupta
Whole Time Director
DIN No. : 80929398

Place : New Delhi
Date: 30.05.2022

4. कर से बाद अन्वधि के लिए शुद्ध लाभ/ (हानि) (विशेष एवं असाधारण मदों के बाद)	1356.71
5. अन्वधि हेतु कुल व्यापक आय (अन्वधि हेतु (कर से बाद) लाभ/ (हानि) एवं अन्य व्यापक आय (कर से बाद से शामिल)	304.60
6. इक्विटी शेयर पूंजी	540.00
7. आरक्षित (पुनर्मूल्यांकन आरक्षित के अतिरिक्त) जैसा कि पूर्व वर्ष के अंतिम तुलन पत्र में दर्शाया गया है।	
8. आय प्रति शेयर (रु. 10/- प्रति का) (जारी तथा अवस्य प्रचालनों के लिए)	
1. मूल:	6.77
2. तरल:	6.77

टिप्पणी:
1. उपरोक्त परिणामों की ऑडिट कमिटी द्वारा समीक्षा की गई तथा 29 मई, 2022 को आयोजित द्वारा अनुमोदित किये गये।
2. उपरोक्त विवरण सेबी (सूचीयन तथा अन्य उद्घाटन अपेक्षा) विनियमन, 2015 के विनियम दाखिल की गई 31 मार्च, 2022 को समाप्त तिमाही तथा वर्ष के स्टैंडप्लान वित्तीय परिणामों व वित्तीय एवं वर्ष वित्तीय परिणामों का संपूर्ण प्रारूप स्टॉक एक्सचेंज की वेबसाइट www.bseindia.com पर उपलब्ध है।

स्थान: नई दिल्ली
तिथि: 29.05.2022

अपू
DIN: 0

जेनोमिक वैली बायोटेक लिमिटेड
पंजीकृत कार्यालय : 4 के.एम. स्टोन, बैरी छॉर रोड, ग्राम-खेड़का मुसलमान, पो.ऑ. टांडाहेड़ी, तहसील-बहादुरगढ़, जिला-झज्जर, हरियाणा-124507
सीआरईएन: L01122HR1994PLC033029; दूरभाष : 491-9811341542
ई-मेल: genomicvalley@gmail.com; वेबसाइट: <http://www.genomicvalley.com> पर मिले
31 मार्च, 2022 को समाप्त तिमाही तथा वर्ष के लिए स्टैंडप्लान अंकेषित वित्तीय परिणामों का विवरण

क्र. सं.	विवरण	समाप्त तिमाही			समाप्त वर्ष	
		31-मार्च-22 अंकेषित	31-मार्च-21 अंकेषित	31-मार्च-21 अंकेषित	31-मार्च-22 अंकेषित	31-मार्च-21 अंकेषित
1	प्रचालनों से कुल आय	55,522	1,030,788	246,116	1,545,710	2,110,026
2	अन्वधि के लिए शुद्ध लाभ/ (हानि) (कर, असाधारण एवं/अथवा अथवा विशिष्ट मदों से पूर्व)	-2,657,363	108,497	-3,263,376	-4,208,275	-5,018,143
3	कर पूर्व अन्वधि के लिए शुद्ध लाभ/ (हानि) (कर, असाधारण एवं/अथवा अथवा विशिष्ट मदों से बाद)	1,534,421	108,497	-3,263,376	-16,492	-5,018,143
4	कर के बाद अन्वधि के लिए शुद्ध लाभ/ (हानि) (कर, असाधारण एवं/अथवा अथवा विशिष्ट मदों से बाद)	1,457,511	108,497	-3,835,747	-93,402	-5,590,514
5	अन्वधि के लिए कुल व्यापक आय (अन्वधि के लिए (कर के बाद) लाभ/ (हानि) तथा अन्य व्यापक आय (कर के बाद से शामिल)	1,457,511	108,497	-3,835,747	-93,402	-5,590,514
6	इक्विटी शेयर पूंजी (30,54,500 इक्विटी शेयर रु. 10 प्रति)	3,054,500	3,054,500	3,054,500	3,054,500	3,054,500
7	आरक्षित (पुनर्मूल्यांकन आरक्षितों को छोड़कर) जैसा कि पूर्व वर्ष के तुलन पत्र में दर्शाई गई है				-1,758,757	14,334,643
8	आय प्रति शेयर					
	(क) मूल	0.48	0.04	-1.26	-0.03	-1.83
	(ख) तरल	0.48	0.04	-1.26	-0.03	-1.83

टिप्पणी:
1. वित्तीय परिणामों के उक्त सारांश की ऑडिट कमिटी के सदस्यों द्वारा समीक्षा की गई तथा उसके बाद 28 मई, 2022 को आयोजित उनकी संबंधित बैठक में निदेशक मंडल द्वारा अनुमोदित किये गए 29 मई, 2022 को कन्सलुड किया गया।
2. उपरोक्त विवरण सेबी (सूचीयन दाखिल एवं उद्घाटन अपेक्षा) विनियम, 2015 के विनियम 33 के अंतर्गत स्टॉक एक्सचेंज में दाखिल की गई तिमाही तथा वार्षिक वित्तीय परिणामों के विस्तृत प्रारूप का सार है। तिमाही तथा वार्षिक वित्तीय परिणामों का संपूर्ण प्रारूप स्टॉक एक्सचेंज की वेबसाइट (www.bseindia.com) तथा कम्पनी की वेबसाइट (www.genomicvalley.com) पर उपलब्ध है।

जेनोमिक वैली बायोटेक लिमिटेड के लिए तथा उसकी ओर से
ह./-
योगेश अग्रवाल
(प्रबन्ध निदेशक)
सीआरईएन : 01165288

स्थान : दिल्ली
तिथि : 30 मई, 2022 पता : जी-74, पुष्कर एन्कलेव, प्रसिद्ध विहार, नई दिल्ली-110063

APEX CAPITAL AND FINANCE
(Formerly Apex Home Finance Limited)
CIN: L65910DL1985PLC021241
Regd. Office: L-3, Green Park Extension, New Delhi - 1100
Email: contact@apexfinancials.in; Website: www.apexfinancials.in

EXTRACTS OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR END

Sl. No.	PARTICULARS	Q1 2022	Q1 2021
1	Total Income from operations	126.3	
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary Items)	15.8	
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	15.8	
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	11.7	
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	11.7	
6	Paid-up Equity Share Capital (Face Value of Rs. 10/- each)	592.0	
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year		
8	Earnings Per Share (of Rs. 10/- each) (for continuing and discontinuing operations)		
	Basic (Rs.)	0.2	
	Diluted (Rs.)	0.2	

NOTES:
1. The above audited financial results for the quarter and year end recommended by the Audit Committee in its meeting held on 29.05.2022 on record by the Board of Directors in its meeting held on 29.05.2022. Company have carried out a statutory audit of the aforesaid financial results.
2. The above is an extract of the detailed format of quarterly & year under Regulation 33 of the SEBI (Listing Obligations and Disclosures) Regulations, 2015. The full format of the Audited Financial Results for the quarter and year ended on March 31, 2022 are available on company's website www.bseindia.com and on the website of the Stock Exchange Website at www.apexfinancials.in.

Date: 29.05.2022
Place: New Delhi

फूटबल परियोजना का स्थान पर रही।

राष्ट्रमंडल खेला में भाग लेंगे और सितंबर में इंग्लैंड के खिलाफ तीन वनडे और तीन टी20 मैचों की संख्या खेलेगी। क्रिकेट आस्ट्रेलिया के सीईओ

खिसकने के कारण अब लाल गेंद के मैच अगले साल फरवरी और मार्च में होंगे। भारतीय पुरुष टीम ने 10 जन तक दक्षिण अफ्रीका के खिलाफ